Mereo BioPharma Group (MREO) Projected to Post Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO) will likely be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Mereo BioPharma Group to post earnings of $0.02 per share for the quarter.

Mereo BioPharma Group Stock Performance

Shares of MREO stock opened at $2.38 on Monday. The company’s fifty day moving average price is $2.79 and its 200-day moving average price is $3.55. Mereo BioPharma Group has a 12 month low of $2.25 and a 12 month high of $5.02.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Lifesci Capital initiated coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, March 18th. Jefferies Financial Group assumed coverage on Mereo BioPharma Group in a research note on Friday, December 6th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $7.83.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.